Lungpacer Medical Inc. is an early-stage medical device company founded in May 2009 and currently headquartered at the Simon Fraser University (SFU) Campus in Burnaby, British Columbia. The objective of the company is to develop and commercialize a novel therapeutic solution that addresses five significant issues associated with mechanical ventilation of critically ill patients.

Intravenously inserted Lungpacer™ electrodes rhythmically activate the diaphragm. In critically ill patients who may fail to wean and become ventilator-dependent, pacing is expected to prevent diaphragm muscle-disuse atrophy, resulting in faster patient recovery, a shorter stay in intensive care, improved health outcomes and lower hospitalization costs. Faster weaning will also increase other patients' access to scarce mechanical ventilators, particularly during major emergencies such as flu pandemics.